The EMD AML approval pathway is where we have already sunk costs for FDA advisors and the FDA strategy meeting regarding an IND. So even with partnership talks we reserve the right to go it alone, at least helpful in negotiations if not reality
- Forums
- ASX - By Stock
- RAC
- Ann: H1 2023 Preclinical and Clinical Programs Update
Ann: H1 2023 Preclinical and Clinical Programs Update, page-42
-
- There are more pages in this discussion • 78 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add RAC (ASX) to my watchlist
|
|||||
Last
$1.75 |
Change
0.010(0.57%) |
Mkt cap ! $298.0M |
Open | High | Low | Value | Volume |
$1.73 | $1.83 | $1.73 | $272.0K | 152.3K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 9998 | $1.75 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.79 | 2000 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 9998 | 1.750 |
1 | 7599 | 1.730 |
1 | 581 | 1.720 |
3 | 11557 | 1.710 |
4 | 46280 | 1.700 |
Price($) | Vol. | No. |
---|---|---|
1.790 | 2000 | 1 |
1.830 | 44030 | 2 |
1.840 | 10500 | 2 |
1.850 | 14500 | 3 |
1.860 | 949 | 2 |
Last trade - 16.10pm 09/07/2024 (20 minute delay) ? |
Featured News
RAC (ASX) Chart |